Literature DB >> 30291335

Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.

Roch Houot1, Guillaume Cartron2, Fontanet Bijou3, Sophie de Guibert1, Gilles A Salles4, Christophe Fruchart5, Krimo Bouabdallah6, Marie Maerevoet7, Pierre Feugier8, Steven Le Gouill9, Hervé Tilly10, Rene-Olivier Casasnovas11, Cécile Moluçon-Chabrot12, Eric Van Den Neste13, Pierre Zachee14, Marc Andre15, Christophe Bonnet16, Corinne Haioun17, Achiel Van Hoof18, Koen Van Eygen19, Lysiane Molina20, Emmanuelle Nicolas-Virelizier21, Philippe Ruminy10, Franck Morschhauser22.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30291335     DOI: 10.1038/s41375-018-0282-y

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.

Authors:  Marek Trněný; Thierry Lamy; Jan Walewski; David Belada; Jiri Mayer; John Radford; Wojciech Jurczak; Franck Morschhauser; Julia Alexeeva; Simon Rule; Boris Afanasyev; Kamil Kaplanov; Antoine Thyss; Alexej Kuzmin; Sergey Voloshin; Kazimierz Kuliczkowski; Agnieszka Giza; Noel Milpied; Caterina Stelitano; Reinhard Marks; Lorenz Trümper; Tsvetan Biyukov; Meera Patturajan; Marie-Laure Casadebaig Bravo; Luca Arcaini
Journal:  Lancet Oncol       Date:  2016-02-16       Impact factor: 41.316

2.  A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Myron S Czuczman; Marek Trněný; Andrew Davies; Simon Rule; Kim M Linton; Nina Wagner-Johnston; Randy D Gascoyne; Graham W Slack; Pierre Brousset; David A Eberhard; Francisco J Hernandez-Ilizaliturri; Gilles Salles; Thomas E Witzig; Pier Luigi Zinzani; George W Wright; Louis M Staudt; Yandan Yang; P Mickey Williams; Chih-Jian Lih; Jacqueline Russo; Anjan Thakurta; Patrick Hagner; Pierre Fustier; Dale Song; Ian D Lewis
Journal:  Clin Cancer Res       Date:  2017-04-05       Impact factor: 12.531

3.  Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.

Authors:  Luca Arcaini; Thierry Lamy; Jan Walewski; David Belada; Jiri Mayer; John Radford; Wojciech Jurczak; Franck Morschhauser; Julia Alexeeva; Simon Rule; José Cabeçadas; Elias Campo; Stefano A Pileri; Tsvetan Biyukov; Meera Patturajan; Marie-Laure Casadebaig Bravo; Marek Trnĕný
Journal:  Br J Haematol       Date:  2017-11-28       Impact factor: 6.998

  3 in total
  1 in total

1.  Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.

Authors:  Loretta J Nastoupil; John Kuruvilla; Julio C Chavez; Fontanet Bijou; Thomas E Witzig; Armando Santoro; Ian W Flinn; Carola Boccomini; Vaishalee P Kenkre; Paolo Corradini; Iris Isufi; David J Andorsky; Leonard M Klein; Daniel R Greenwald; Randeep Sangha; Frank Shen; Patrick Hagner; Yan Li; Juergen Dobmeyer; Nian Gong; Shailaja Uttamsingh; Michael Pourdehnad; Vincent Ribrag
Journal:  EJHaem       Date:  2022-02-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.